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Abstract 
Background: Human papillomavirus  (HPV) vaccine  is a newly  introduced vaccine 
against  cervical  cancer  in  adolescent  girls.  Uptake  of  the  vaccine  will  be 
dependent on parental acceptability and physician recommendation.  
Objective:  To  review  physicians’  attitudes  towards  HPV  vaccine  and  identify 
factors  that  may  influence  their  intent.  Also,  to  determine  if  there  is  any 
difference  in  the  views  of  different  medical  specialties  with  regards  to  HPV 
vaccination. 
Search  Strategy:  Articles  were  obtained  through  computerised  searches  of 
CINAHL,  Pubmed, Web  of  Knowledge,  Cochrane  Library  and  Science Direct,  as 
well as manual searches in recognised scientific journal.  
Selection  criteria:  Articles  involving  physicians’  attitudes,  knowledge  and 
behaviour towards HPV vaccine published from 2007 onwards.  
Data  extraction: One  reviewer  independently  assessed  relevant  studies,  risk of 
bias and data extraction. 
Main Results: Twenty nine studies were included in the final review. Twenty four 
studies used survey  for data collection and  five studies used  interview. Majority 
of the studies revealed positive view of physicians towards HPV vaccine with high 
intent to provide vaccination. Barriers  identified against HPV vaccination  include 
the  following:  cost  and  reimbursement  issue;  providers  concern  about  vaccine 
safety; parental concern over vaccine’s safety and efficacy; age is considered too 
young  for  vaccination;  issue  that  HPV  vaccine  could  promote  sexual  activity, 
recommendation of HPV  vaccine  from organisations;  communication  related  to 
sexuality; need for education and other factors like dosing, patient overload, boys 
should also be vaccinated and parental religious beliefs. No significant difference 
was noted between specialties with regards to their view about HPV vaccine. 
Conclusion: Physicians’  role  is  important  in  the promotion of HPV  vaccine with 
their  high  intent  and  positive  attitudes.  In  order  for  the  HPV  vaccination 
programme  to  succeed,  vaccine  should  be  made  available  and  affordable 
especially to countries with high incidence of cervical cancer. 
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1. INTRODUCTION 
Public Health is defined as the “science and art of preventing disease, 
prolonging life and promoting health through the organized efforts and 
informed choices of society, organisations, public and private, communities 
and individuals” (Wanless,  2004, p.7)  
The focus of public health activities is aimed at preventing problems from 
emerging or at least preventing their most serious consequences (Baggot, 
2010).  Three types of prevention have been established in public health, the 
primary, secondary and tertiary prevention. Yamell and Evans (2007), 
described primary prevention as preventing the onset of disease through 
immunisation against  infectious disease or tropical disease; secondary 
prevention is involved in early detection of disease,  slowing down or 
interrupting the natural progression of disease through screening for early 
tumours or raising symptom awareness  and finally, tertiary prevention is 
preventing the major consequences of an established disease, for example, 
rehabilitation of patients with disability or long term management of chronic 
illness. 
  Vaccination was recognized as one of the ten great public health 
achievements for the 20th century (Centres for Disease Control and 
Prevention, Ten great public health achievements, 1999).  Hence, with the 
emphasis of Public Health on the prevention of illness rather than treatment, 
this research paper will focus on the primary prevention of cervical cancer 
through immunisation with Human papillomavirus vaccine. 
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The linked between Human papilloma virus (HPV) and cervical cancer was 
well documented biologically and epidemiologically (Franco, Rohan & Villa, 
1999) and concluded by the International Agency for Research in Cancer 
(IARC) [Studies of Cancer in Human-IARC Monographs]. Human 
papillomavirus are double-stranded, nonenveloped DNA viruses in the family 
Papillomaviridae. HPVs isolates are classified as “types” and assigned 
numbers signify their order of discovery (de Villiers, Fauquet, Broker, 
Bernard, Zur, 2004).   HPV 16 and 18 were implicated as the causative 
agents in 70 percent of cases of cervical cancer globally. Together, HPVs 
16, 18, 31, 33, 45, 52 and 58 account for about 90 percent of cases 
worldwide.  While, HPV 6 and 11 are the two types with low oncogenic 
potential which causes 90 to 100 percent of external anogenital warts and 
nearly all cases of recurrent respiratory papillomatosis (World Health 
Organization HPV Vaccine Background Paper, 2008). 
 Furthermore, according to the World Health Organization (WHO: Human 
Papillomavirus Vaccine Background Paper, 2008), genital HPV infections 
are highly transmissible with penetrative and non-penetrative sexual contact. 
It is the most common viral infection of the genital tract. Incidence and 
prevalence increases with increasing sexual activity and most sexually active 
men and women will acquire the infection at some time in their lives. The use 
of condoms can reduce the transmission of HPV infection between partners, 
however, they are unlikely to provide complete protection against 
transmission of infection (Winer, Hughes, Feng et al., 2006).  
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 Most HPV infections of the cervix are asymptomatic and transient, within 
two years, infection may clear and no longer be detectable by commonly   
used molecular methods. However, persistent HPV infection can lead to the 
development of precancerous lesions, cancer, notably cervical cancer. The 
WHO (Cervical cancer, Human papillomavirus and HPV vaccine key points 
for policy makers and health professionals, 2008) listed factors associated 
with persistence of HPV and development of cervical cancer as immune 
suppression, multiparity, early age at first delivery, long term use of 
hormonal contraceptives, cigarette smoking and infection with other sexually 
transmitted diseases. It would take a decade for an HPV infection to develop 
into a cervical cancer.  
 The World Health Organization states in its November 2010 Summary 
Report that cervical cancer is the second most common cancer in women 
worldwide. Cervicalcancer.org (2007), reported that a woman dies of cervical 
cancer every 2 minutes around the world. Recently, Global Cancer 
(GLOBOCAN 2008) factsheet showed cervical cancer as the third most 
common cancer in women and the seventh overall. More than 85 percent of 
the global burden occurs in developing countries where it accounts for 13 
percent of all female cancer. Mortality incidence ratio is 52 percent in 2008, 
about 88 percent of deaths occur in developing countries. If current mortality 
trends continue, this proportion is expected to increase to 90 percent by 
2020. Moreover, 60 percent of women with cervical cancer will die of their 
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disease in developing countries due to late detection (WHO: HPV vaccine 
Background Paper, 2008). 
The U.S. Food and Drug Administration (FDA) in June 2006 approved the 
use of the first prophylactic quadrivalent HPV vaccine in 9 to 26 year old 
females. This vaccine contains virus-like particles (VLP) for HPV types 6, 11, 
16 and 18 to prevent cervical precancers and cancers and anogenital warts 
in females as well as prevention of vulvar and vaginal precancers and 
cancers. This vaccine was also licensed for the prevention of anogenital 
warts in males in some countries. As of March 2008, this vaccine was 
licensed in more than 90 countries (Human papillomavirus vaccines: WHO 
position paper, 2009). 
In April 2007, another prophylactic bivalent vaccine was first licensed in 
Australia, which contains virus-like particles of HPV types 16 and 18. This 
vaccine has been licensed for use in females for the prevention of cervical 
precancers and cancers as young as 10 years of age. Unlike the 
quadrivalent vaccine, recommendation for use in males has not been 
sought. By March 2008, the use of bivalent vaccine was licensed in 40 
countries (Human papillomavirus vaccines: WHO position paper, 2009).  
 Both vaccines are generally well tolerated and have good safety profiles as 
concluded by the WHO’s Global Advisory Committee on Vaccine Safety 
(June 2007). Likewise, both vaccines are indicated to be administered before 
first exposure to HPV infection, that is, before the onset of sexual activity or 
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sexual debut. Some countries recommend vaccinating “catch-up” 
populations of older females within the range of 13 to 26 year old, 
emphasizing the benefits offered to those who may not yet be infected. 
Three doses are recommended and completed within 6 months. However, 
the Centre for Disease Control and Prevention in the USA reported that 
there is a high coverage among girls who received at least one of three 
necessary doses of an HPV vaccine (7 to 44 percent) but for girls who 
received three doses coverage was only 27 percents.  At present, following 
completion of the primary series of vaccination, a booster dose is not 
recommended by the manufacturers. 
In UK, routine nationwide vaccination programme for HPV vaccine was 
launched in September 2008, offered to girls in 12 to 13 years old in schools. 
According to the joint Department of Health and Health Protection Agency 
(HPA) annual report 2010, over 60 percent of all females completed the 
three-course of HPV vaccination during the first two years of the HPV 
programme. 
 In the United States, the 2010 overall coverage among girls 13 to 17 for 3 
doses of HPV vaccine was 32 percent. In Canada, after the first year of the 
programme the national coverage varied with a range of 80 to 85 % reported 
in the Atlantic provinces and 51 % in Ontario.  In Panama, the coverage was 
67 % for 3 dose HPV vaccination in year 2010. For the first year of 
vaccination programme in Mexico in 2008, it had 81% coverage for 3 doses 
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of vaccines (Centres for Disease Control, 2010). Spain reported that during 
the first year of the HPV vaccination, three dose vaccination coverage was 
77.3% for the targeted adolescent girls (Limia & Pachon, 2011). 
Being a newly introduced programme for vaccination, uptake is vital for the 
programme to be effective. Success of HPV vaccines in reducing the 
incidence of cervical cancer will be dependent on its uptake. Jit, Choi and 
Edmunds (2008), estimated that for HPV vaccination programme to be 
effective, 80 % coverage should be achieved. A similar study suggested that 
to attain an indirect benefit to unvaccinated women who may experience a 
reduced risked to vaccine-preventable types or herd immunity, vaccine 
coverage should be between 50 to 70 percent (Boogards et al., 2011). 
  Acceptability of the target populations and their parents or guardians 
towards the vaccine is an important factor if high vaccination coverage 
should be achieved. As the vaccine is targeted at young adolescents, 
parental acceptance is of primary consideration. Parents’ cited reasons for 
declining vaccination as lack of knowledge about HPV, age-related concerns 
and low perceived risk of infection. Nevertheless, motivating factors 
identified were desire to prevent illness, physician recommendation and high 
perceived risked of infection (Dempsey, Abraham, Dalton, Ruffin, 2009).  
Parents, particularly mothers were identified as single factors that heavily 
influence these young girls with regards to vaccination. It was further 
emphasized that “the gateway to the adoption of the vaccine is through the 
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parents” (Chollette, 2011). In addition, Ogilvie et al. (2008)   particularly 
pointed out parental attitudes towards HPV vaccine as the strongest 
predictor of parental intention to vaccinate but health care professionals, 
particularly physician’s recommendation in favour of HPV vaccination was 
also emphasized. Those parents with vaccinated daughters had higher HPV 
vaccine knowledge and were likely to have received recommendation from 
their paediatrician (Gerend, Weibley & Bland, 2008). 
 Clearly, physicians are well situated in a position to be in contact point with 
the target populations. Hence, they have a key role in influencing parents 
and adolescent girls in increasing awareness to the HPV vaccination 
programme and intentions to accept vaccination. 
 In the United Kingdom, HPV vaccine delivery is school-based.  
Consequently, the school nurses are mostly responsible for delivering the 
HPV vaccine to 12 to 13 year old girls.  A qualitative study was done in two 
Primary Care Trust (PCT) in the UK to assess the impact of HPV vaccine on 
school nurses’ role revealed that uptake between schools reflects the difficult 
relationships with the school nurse, primarily attributed to schools’ attitudes 
to health interventions, characteristics of the school, organizational problems 
and multiple school nurse roles and/or personal ability (Brabin, et al., 2011). 
Another qualitative study was conducted to explore school nurses’ 
experiences of delivering the UK vaccination programme in its first year 
through telephone interviews. Unlike the previous study, this study showed 
 
8 
 
that across UK, implementation of HPV vaccine in its first year exceeded 
school nurses expectations and success of the programme was ascribed to 
school nurses’ commitment to the programme. Aside from the nurses’, this 
study considered positive newsprint media reporting that accompanied HPV 
introduction as contributory factor to the success of the programme. 
However, both studies, agreed that HPV vaccination programme had vastly 
increased school nurses workload leading them to cut back on their core 
activities (Hilton, Hunt, Bedford, Petticrew, 2011). 
Nevertheless, for the purpose of this review, physicians’ attitudes, largely, 
the primary care physicians, paediatricians and obstetricians attitudes 
toward HPV vaccine will be considered.  
From a survey of verified U.S. physicians online in 2006, variables 
investigated as predictors of physicians’ intention to vaccinate included 
perceived child risk for HPV, perceived benefits outweighing the risk of the 
vaccine, perceived severity of HPV, perceived effectiveness of the vaccine in 
preventing cervical cancer, perceived parental fears about the vaccine 
encouraging sexual activity, whether they would vaccinate their own child 
against HPV and physician specialty. Cost of the vaccine was also 
considered (Barnack, Reddy & Swain, 2009). 
Availability of human papilloma vaccine has positioned the primary care 
physician to ensure its implementation and success (Carderelli & Carderelli, 
2008). Recent findings about parental knowledge, attitudes and behaviours 
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revealed declining patterns in parental awareness, uptake and intent for HPV 
vaccination. Furthermore, there is a call for physicians to provide more 
information about the safety of the vaccine (Trim, Nagji, Elit and Roy, 2011), 
thus, making this review about physicians’ attitude towards HPV vaccine 
more opportune.  Therefore, whether physician could foster or hinder in the 
success of the HPV vaccination programme is an interesting matter to 
explore. 
 
 
 
 
 
 
 
1.1 Background Literature 
Prior to the approval of HPV vaccines, various studies were conducted to 
look at family physicians attitudes about HPV vaccination and to identify 
predictors of intent to recommend the vaccine (Riedesel, Rosenthal, Zimet, 
Bernstein, Huang, Lan & Kahn, 2005) and another study assessed 
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paediatricians intention to administer the HPV vaccine (Kahn, Zimet, 
Bernstein, Riedesel, Lan, Huang & Rosenthal, 2005). In both these studies 
done in the US family physicians and paediatricians demonstrated positive 
intent to recommend the vaccines.   
A four-fold greater likelihood of vaccination when women received a strong 
recommendation from the physician shows the strength of the physician’s 
recommendation and a significant role he or she played in the decision for 
vaccination (Rosenthal, Weiss, Zimet, Ma, Good & Vichnin, 2011).  
Eighteen months post-licensure of HPV, vast majority of paediatricians and 
family physicians reported offering the vaccine (Daley et al., 2010), however, 
physicians’ were not routinely providing HPV information to their female 
patients as found out when women were assessed regarding their 
perceptions of the education they received from their physicians regarding 
HPV infection, risk factors and prevention (Cermak, Cotrell & Murnan, 2010).  
It is a challenge to provide information to ensure that individuals understand 
the potential benefits of HPV vaccination which should ultimately determine 
the success of the immunization programme (Brown, Little & Leydon, 2010). 
Research about physician’s intent to vaccinate has been investigated in 
different settings. Hopkins, Wood, West and Darling (2009), conducted an 
online survey in the UK to three medical professional groups, which 
demonstrated that over 90% supported vaccination of girls as early as ages 
11 to 13. In addition, doctors’ self-rated knowledge of the HPV vaccine was 
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an important determinant of willingness to recommend vaccination. Likewise, 
the study showed that younger, more recently qualified doctors were less 
likely to be willing to recommend vaccination. In contrast, younger physicians 
were more likely to discuss about HPV infections, risks and prevention with 
women than older physicians (Cermak, Cottrell &  Murnan, 2010).   This 
survey could serve as a basis for improving doctors’ confidence in 
recommending HPV vaccine by providing more information especially to 
junior doctors. 
Driven by the low US uptake of 6 to 25 percent on the first year of vaccine 
introduction despite national recommendations for universal vaccination of 
adolescent girls 11 to 12 year-old girls, a state-wide survey about physicians’ 
recommendation was done in Texas, U.S.A. that would help provide 
information on intervention to improve   recommendation that would in turn 
improve uptake. The study revealed that half of the physicians’ did not follow 
current recommendations for universal HPV vaccination. In addition, 
education and policy interventions were the factors related to vaccine 
recommendations (Kahn, et al., 2009).  
Attitudes of Arkansas’ primary care physicians towards the HPV vaccine was 
also surveyed in 2009. Results showed that significant barriers to HPV 
vaccine administration are cost and perceived low compliance to the dosing 
schedule. Furthermore, this study recommends vaccine funding for patients 
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and physicians which is a primary issue and steps should be taken to 
increase vaccine affordability (Tariq, Bhakta, Grimes & Stevens, 2009). 
Physicians’ have reiterated in several studies that cost or financial burden of 
immunization and safety of the vaccine were factors considered as barriers 
of HPV immunization (Jaspan, Dunton & Cook, 2008; Leddy, Anderson, 
Power, Gall, Gonik, & Schulkin, 2009). 
Paediatricians’ intent   to recommend HPV and factors influencing their 
decisions were explored using a qualitative study in the USA. Primary factors 
driving paediatricians’ decision about recommending HPV vaccines are: 
efficacy, safety and potential health impact of the vaccination, perceived 
benefits of HPV vaccination included prevention of HPV-related disease and 
the opportunity to educate adolescents. Anticipated parental belief (e.g. 
parental denial that their child would be at risk) and providers’ belief like 
reluctance to discuss sexuality with preadolescents are the perceived 
barriers mentioned. High intent to recommend the vaccine was also one of 
the findings from this study. The main factors driving intention to recommend 
HPV vaccines included knowledge, personal and professional 
characteristics, office procedures, vaccine cost and reimbursement, parental 
factors and specific attitudes about HPV vaccines. (Kahn, Rosenthal, Tissot, 
Bernstein, Wetzel & Zimet, 2007) 
To investigate issues surrounding HPV vaccine delivery in a multi-ethnic, 
multi-religious and multi-cultural society in Asia, a qualitative in-depth 
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interview study was conducted. Physicians rated success of HPV 
recommendations as very poor. Many expressed reluctance to offer the 
vaccine to preadolescents. The high cost of the vaccine was the most 
notable barrier. Being a new vaccine, parents of eligible target populations 
were concerned about its efficacy and side effects. This study recommends 
the need to strengthen the infrastructure necessary for HPV vaccine delivery 
and specifically target poor underserved women (Wong, 2011). 
Numerous studies have proliferated to evaluate and assess healthcare 
providers’ knowledge, attitudes, and experience with regards to the new 
HPV vaccination programme. In order to synthesize, and understand fully, 
issues surrounding these healthcare providers’ attitudes and vaccine 
delivery, a systematic review will be carried out. 
 
 
 
 
1.2 What is HPV vaccine? 
Human papillomavirus vaccines are newly licensed vaccines against HPV 
infections. These vaccines are prophylactic and not intended to use as 
treatment in women with existing HPV infection or to treat HPV related 
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disease. According to Mc Neil (2006), four claimants were recognized as the 
inventors of HPV vaccine, the National Cancer Institute; Georgetown 
University in Washington, DC;   Queensland University in Brisbane, Australia 
and University of Rochester in New York.  
Currently, there are two available HPV vaccines marketed worldwide, the 
Quadrivalent HPV vaccine (HPV4; Gardasil, Merck & Co, Inc.) and the 
Bivalent HPV vaccine (HPV2; Cervarix, GlaxoSmithKline). 
Quadrivalent HPV vaccine provides protection against two oncogenic types 
HPV 16 and 18 and two non-oncogenic types HPV 6 and 11 while the 
bivalent HPV vaccine protects against two oncogenic types, HPV 16 and 18. 
Both vaccines have high efficacy against HPV 16 and 18- related cervical 
precancer lesions while quadrivalent HPV vaccine has high efficacy against 
HPV 6 and HPV 11-related genital warts and HPV 16 and 18- related vaginal 
and vulvar precancer lesions (Centre for Disease Control, 2007). 
The mechanism by which these vaccines induce protection have not been 
fully defined but seem to involved both cellular immunity and neutralizing 
immunoglobulin  G antibodies (Stanley, Lowy & Fraser, 2006; Olsson, Villa, 
Costa, Petta, Andrade, Malm, et al., 2007) 
Since both vaccines are composed of virus-like particles and are not live 
virus, they have good safety profiles and cannot cause a disease.  
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Advisory Committee on Immunization Practices (ACIP) recommends 
vaccination of females age 11 or 12 years with three doses of either 
quadrivalent or bivalent HPV vaccine. As early as 9 years of age, vaccination 
can be started. Given that HPV vaccines are most effective for females who 
are naive to vaccine-related HPV types, selection of the target population 
should be based on data on the age of initiation of sexual activity as 
suggested by WHO.  Hence, the primary target population is likely girls 
within the age range of 9 or 10 years through 13 years (Conclusion: 
moderate quality of scientific evidence to support HPV vaccination of young 
adolescent girls to prevent cervical cancer later in life). 
The administration schedules and dosing are similar for both vaccines. The 
route of administration is intramuscularly with the deltoid muscle as preferred 
site. Each dose is 0.5 ml, administered in a three-dose schedule.  The 
second dose is administered 1 to 2 months after the first dose and the third 
dose is administered 6 months after the first dose (ACIP, 2010). In a 
situation where the HPV vaccine schedule is interrupted the vaccine series 
does not need to be restarted. 
HPV vaccines are contraindicated in pregnant women and those who have 
experienced severe allergic reactions after previous vaccine dose or to a 
component of the vaccine. Lactating women could be administered the 
quadrivalent vaccine as safety data for bivalent vaccine are not yet available 
(Human papillomavirus vaccines: WHO position paper, 2009). 
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Furthermore, In countries where both vaccines are licensed, the choice 
between the two vaccines should be based on the assessment of a number 
of factors which includes the scale of the prevailing HPV problem (cervical 
cancer, other anogenital cancers or anogenital warts); the population for 
whom the vaccine has been approved (girls 9 or 10 through 13 years or 
older females, women, and/or males); delivery strategies, data on vaccine 
efficacy against HPV-related diseases and safety in subpopulations eligible 
for vaccination (Human papillomavirus vaccines: WHO position paper, 
2009). 
On October 2009, the Food and Drug Administration licensed quadrivalent 
HPV vaccine for use in males aged 9 through 26. Few days later, Advisory 
Committee on Immunization Practices (ACIP) provided guidance that 
quadrivalent HPV vaccine may be given to males aged 9 through 26 to 
reduce their likelihood of acquiring genital warts but does not recommend 
quadrivalent vaccine for routine use among males. Efficacy, immunogenicity, 
safety of quadrivalent HPV vaccine in males, epidemiology of HPV and 
burden of HPV associated diseases and cancers in males, cost 
effectiveness of male vaccinations and programmatic considerations were 
the issues reviewed by the Advisory Committee on Immunization Practice 
with regards to HPV vaccination in males. (CDC, MMWR, 2010)  
Centres for Disease Control and Prevention listed HPV vaccine as the most 
expensive vaccine available (www.cdc.gov/vaccines/programs/vfc/cdc-vac-
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price-list.htm), making its price to high income countries unaffordable for low 
to middle income countries. However, efforts are being made to provide 
vaccines especially in areas with disproportionate burden of cervical cancer. 
 
 
 
 
 
 
 
 
 
1.3 Implementation of HPV vaccine 
Along with the licensure of HPV vaccines by the Food and Drug 
Administration (FDA) on June 2006, the Advisory Committee on 
Immunization Practices (ACIP) provided    recommendations on its use 
among females 9 to 26 years old in the United States. The World Health 
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Organization published a background paper about HPV that include key 
points and evidence most relevant to the World Health Organization 
Immunization Strategic Advisory group of Experts in 2008.  Human 
Papillomavirus vaccines: WHO position paper was presented in 2009, 
providing more comprehensive information about the HPV vaccine 
particularly its recommendation as a new vaccine. 
The introduction of HPV vaccine was supported  with expansion of 
immunization programme beyond infancy and early childhood by 
WHO/UNICEF Global Immunization Vision and Strategy (GIVS);  WHO’s 
Vaccine Preventable Disease Categorization Project, which ranked cervical 
cancer as 1 of 10 “high-priority” diseases and guided  Global Alliance for 
Vaccines and Immunisation GAVI’s new investment strategy; WHO’s Global 
Reproductive Health Strategy for the Prevention and Control of Sexually 
Transmitted Infections and Millennium Development Goals to combat 
disease characterized by socioeconomic inequity and to promote gender 
quality, empower women and improve maternal health (HPV vaccine, WHO, 
Background paper, 2008).  
According to the WHO, decisions on the introduction of vaccine on each 
country must consider vaccine affordability and financing sources, the 
financial and operational impact on the delivery systems of immunizations, 
child and adolescent current immunization services and requirements to 
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develop new delivery systems for the primary target population. (HPV 
vaccine, WHO, Background paper, 2008) 
Moreover, in recognition to the importance of cervical cancer and other HPV 
disease as global public health problems, the WHO recommends that routine 
HPV immunization should be included in the national immunization 
programmes. 
It would be difficult to compare HPV vaccination programmes between 
countries because of the different vaccine delivery systems. Countries like 
UK, Australia and Canada have school based programmes for delivery of 
vaccines while the US has the paediatric and family medicine primary care 
provider clinic to administer the vaccines.  
Regional consultations about cervical cancer and HPV vaccines by the WHO 
on 2008 pointed out, that to maximized vaccine delivery, a school based 
programmes would be promising. Kadis et al., (2011) suggested that most 
parents who support HPV vaccination for adolescents find school-based 
vaccination an acceptable option. Crosbie and Babin (2009) attributed high 
level of uptake in England for the first cohort of 12 to 13 year old girls who 
were offered HPV vaccine to the fact that the vaccine was offered in schools 
in the majority of Primary Care Trust. 
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1.4 Uptake of HPV vaccine? 
Success in controlling cervical cancer would only be achieved if the vaccine 
have good uptake. At the same time, uptake of HPV vaccine is strongly 
influenced by its acceptability. Brewer and Fazekas (2007), listed factors that 
would increase HPV vaccine acceptability such as the effectiveness of the 
vaccine, the physician’s recommendation and the risk of HPV infection.  
The United States had reported an increase of coverage since it was 
introduced in 2006. Limia and Pachon (2011), cited that in the first year of 
HPV vaccination programme in Spain, 77.3 percent of target adolescents 
were given three doses of the vaccine. Furthermore, during the first year of 
the programme, other countries showed variable coverage for three doses in 
the respective target groups as follows: 44 percent in Belgium; 53.1 percent 
in Italy and 80.9 percent in the UK.  
 
 
 
 
1.5 Burden of cervical cancer 
GLOBOCAN reported that in 2008, there were 530,000 new cases of 
cervical cancer and 275,000 deaths. More than 85 percent of the global 
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burden occurs in developing countries. The high risked regions are Eastern 
and Western Africa; South Africa; South-Central Asia; South America and 
Middle Africa.  Those with low rates regions are Western Asia; North 
America; Australia and New Zealand. 
 More than 260,000 cervical cancer deaths occurred in 2005, according to 
WHO, if this trend continues, by 2050 incidence of cervical cancer will rise to 
an estimated 1 million cases per year (WHO: HPV, Background Paper 
2007). 
Likewise, women over 40 years of age are the most commonly diagnosed 
with cervical cancer, an age when women maximize their familial, economic, 
social and educational contributions. 
 
 
 
 
1.6  Why are physicians role important in the success of HPV 
vaccination        programme? 
For an immunization delivery system to be effective, it must address the 
needs of both the target populations and primary care practitioner (Orenstein 
& Rodewald, 2000). Physicians, aside from the nurses are frontline 
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personnel who could influence parents and adolescent girls in their intent for 
vaccination, provide information and offer advice. From the point of view of 
the physicians, suggested factors that would influence their decision in the 
delivery of adolescent immunization would be organizational 
recommendations, vaccine cost and reimbursement, disease characteristics 
as well as vaccine characteristics.  (Humiston, et al., 2008).  
Although the role of primary care physician is substantial for the campaign, 
implementation and delivery of the HPV vaccine, two particular specialties 
are particularly involved with HPV vaccine. First, the paediatricians, since 
these age group still covers the age catered by this specialties and secondly, 
the obstetricians-gynaecologist as this specialty  are concerned about 
women’s’ reproductive health and diseases.  
Adolescent is defined by the WHO as a person between 10 to 19 years old.  
Knowledge and clinical skills requires for the medical care of adolescents, 
rest mostly on the practice of paediatrics. Although, gynaecologist were seen 
as the most appropriate figure to provide information about HPV infection, 
there is still preference for the paediatricians as immunization provider, 
which could be explained by  the observation that from birth,  paediatricians  
has been around to provide health care  to these age groups(Tozzi, Rava, 
Stat, Pandolfi, 2009). 
Communicating about HPV vaccine to parents and adolescent girls which 
relates to sexually transmitted infection would posed a challenge. Parents 
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concern that by consenting to vaccination, adolescents will be predispose to 
risky sexual behaviour. 
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2.0 RATIONALE AND AIMS 
Several studies relating to physicians’ attitudes about HPV vaccination 
programme pre- licensure and post-licensure of the vaccine   has conclusive 
findings and conflicting results. “The systematic review is now widely 
considered within policy and practice circles to be a good way of making the 
sometimes conflicting and complicated results of many different types of 
study accessible and more useable” (Bambra, 2011, p.14). Moreover, the 
same author gave the definition of systematic review in simple terms as “a 
method of locating, appraising and synthesising evidence”. One reason why 
the systematic review is becoming more popular and established research in 
public health policy and practice is in its emphasis on ‘evidence-based’ 
decisions and interventions. Thus, the purpose of this review is to synthesize 
evidence generated from previous researches, to determine if they possess 
relevant information regarding the questions below: 
1. What are physicians’ attitudes towards HPV vaccination? 
2. What are the factors that influence physicians’ decisions in administering 
HPV       vaccine? 
3. Is there difference in the views of different medical specialties with 
regards to             HPV vaccination? 
This has been achieved through a systematic review of particular and 
relevant studies in accordance to a strict inclusion and exclusion criteria. As 
to date, no systematic review has been done about physicians’ attitudes 
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towards HPV vaccination. The focus of this review is on studies done after 
the approval of first HPV vaccine on 2006.  
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 3.0 METHODOLOGY 
This section of the review will be used to explain the methods which were 
used in searching relevant articles used for analyses and evaluation as well 
as how the papers were searched for and selected. This will ensure that all 
studies have been selected for inclusion and quality assessed and those 
papers that did not qualify will not be included. 
Prior to searching for related articles, subject librarian assistance was 
consulted for a comprehensive search strategy. With the research question 
as a guide for selecting keywords, a concept map was planned for searching 
articles. Adapted from the University of Illinois Concept Map, it is a guide that 
will help the researcher to brainstorm the topic and identify what concept or 
keywords to use for searching the information. Furthermore, it will also help 
to identify what is already known about the topic as well as provides an 
opportunity to think about the topic in new ways and identify gaps in 
knowledge. Thus, making the information search more effective and efficient. 
The modified concept map, provides, as well a checklist for resources to 
search for information and will help keep tract on the databases listed. An 
example of a concept map is in appendices. 
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  3.1 Search Strategy 
The first step is to write the topic and encircle the keywords or key phrases. 
In this review, the keywords or key phrases encircled were “physician” and 
“Human papillomavirus vaccine” and “attitudes”.  The next step is to write the 
key words that were encircled in boxes provided and list other terms that can 
be used to describe the keywords. To compile the keywords to search, the 
author’s own knowledge of the area of research, the medical subject 
headings (MeSH) on-line vocabulary and guidance from the subject librarian 
were utilised. The following text words for physician and HPV vaccine can be 
found in table 2. 
Table 1 Keywords and synonyms 
 
 
Physician Human papilloma virus vaccine Attitudes 
Doctor* HPV vaccine views 
Clinician*  knowledge 
Obstetrician*  perceptions 
Paediatrician*   
General practitioner*   
Family physician*   
Primary care staff*   
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 3.2 Search Methodology 
The first and second step in performing journal search by using concept map 
as a guide had been performed. The final step is to list the resources 
planned to search for information. For this review, the resources/ databases 
listed were: Cumulative Index to Nursing and Allied Health Literature 
(CINAHL), Pubmed, Web of Knowledge, Cochrane Library and Science 
Direct. 
The above key words have been combined using Boolean logic (AND, OR, 
NOT) to create a set of results that should contain articles relating to the 
topic in question. The AND operator is used to ensure that all search terms 
must appear in the record as demonstrated below. The OR is used to 
accumulate similar terms and thus make the search larger.  This will 
retrieved all records with physician, general practitioner, obstetrician, 
paediatrician, primary care staff, primary care personnel or all of these six 
were found.  
In order to improve search results and make database searches more 
efficient, truncation and wildcard symbol (*) were also used. Truncation 
which is also called stemming is a technique that could help broaden 
searches by including various word endings 
(www. memphis.edu/instructionalsvcs/pdfs/symbols.pdf). 
 For example in this search, by placing the symbol (*) at the end of the word 
physician, database will return results that include physician and physicians. 
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 Therefore,   the search terms would appear as:  
“Human Papillomavirus vaccine” OR “HPV”  
AND “Physician*” OR “General Practitioner*” OR “clinician*” OR 
“Obstetrician*” OR “Paediatrician*”OR “Primary care staff*”  
AND “attitude*” OR “views” OR “perceptions”.   
The operator NOT is used to exclude records from the search. For example 
in the search “Human papillomavirus vaccine”  NOT  “Human papillomavirus 
screening”, would retrieved all records which contained the term Human 
papillomavirus vaccine and not those which contained the term Human 
papillomavirus screening. 
When searching database, the keywords were searched in all text of the 
journals not just in the title and abstract in order to retrieve more relevant 
articles.  However when this refinement option was not available the search 
was extended to the entire document 
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3.3. Database search 
The third step in searching for journals using the concept map is to list the 
resources planned to search for information. As mentioned, these databases 
include CINAHL, Pubmed, Web of Knowledge, Cochrane and Science 
Direct. These online databases were selected from subject resources for 
Public Health Research from the university intranet. Journals were searched 
in these five databases which will be described below to provide 
understanding why specific databases were chosen, followed by searches 
into specified journals.  
CINAHL Plus with Full Text (www. ebscohost.com), the Cumulative Index to 
Nursing and Allied Health Literature is the most comprehensive resource for 
nursing and allied health literature. Providing more than 2.8 million records 
dating back to 1981; full text for more than 770 journals; full text for more 
than 275 books and monographs; full text coverage dating back to 1937 and 
indexing for more than 4600 journals.  It also includes searchable cited 
reference on more than 1350 journals. 
This database covers nursing, biomedicine, health sciences librarianship, 
alternative or complementary medicine, consumer health and 17 allied 
medicines.  
Pubmed (www.ncbi.nlm.gov) is a major database for medical and bioscience 
literature. This database provides reference usually with abstracts and links 
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to the full text of some articles. It comprises more than 21 million citations for 
biomedical literature from MEDLINE, life science journal and online books. It 
is a free access internet version of MEDLINE, also including records from 
before 1966 (old MEDLINE), some very recent records and some of other 
life sciences journals. 
MEDLINE is an electronic database produced by the United States National 
Library of Medicine (NLM). It indexes millions of articles in selected journals 
available through most medical libraries and can be accessed on the 
internet. 
Web of Knowledge (www.wokinfo.com) contains Web of Science and 
MEDLINE. This database provides searchable index of science, social 
sciences and arts and humanities citations. It covers a broad subject area 
and covers 23,000 journals; 23 million patents; 148,000 conference 
proceeding; 40 million source items;  760 million cited reference; 9,000 
websites; more than 250 product categories and 256 product categories. 
The Cochrane Library (www.thecochranelibrary.com), is  a collection of 
databases published on CD-ROM and the internet and updated quarterly, 
containing the Cochrane Database of Systematic Reviews, the Cochrane 
Central Register of Controlled Trials, the Database of Abstracts of Reviews 
of Effects, the Cochrane Methodology Register, the Health Technology 
Assessment Database, NHS Economic Evaluation Database and 
Information about the Cochrane collaboration. 
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This data base is the source of evidence about the effects of health care. It 
also includes the full text of systematic reviews of clinical trials. 
Science Direct (www.sciencedirect.com), is a leading full-text scientific 
database offering journal articles and book chapters from more than 2500 
peer-reviewed journal and more than 11,000 books. There are more than 9.5 
million articles and chapters. Over 1,500 full text science and medical 
journals could be accessed on this data base. 
 
 
3.4 Journal Articles 
In order to recover other published articles that were not retrieved through 
database, journal articles that are specific to the topic investigated in this 
particular review such as physicians, HPV vaccines and views were 
searched through individual academic journals which are listed below:  
 
• Vaccine 
• The Lancet 
• Journal of Adolescent Health 
• International Journal of Gynaecology and Obstetrics 
• Journal of Paediatric and Adolescent Gynaecology 
• Ambulatory Paediatrics 
• European Journal of Obstetrics and Gynaecology 
• Clinical Journal of Oncology Nursing 
• Journal of Women’s Health 
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Supplemental searches were done for this particular review in order to 
collect more relevant articles, such as hand searching for journals, searching 
in websites and citation follow up. Unpublished articles were also sought by 
using the US ClinicalTrials.gov (http://clinicaltrials.gov/ct2/info/about) and the 
United Kingdom’s National Research Register (NRR) Archive 
(http://www.nihr.ac.uk/Pages/NRRArchive.aspx). 
 
 
3.5. Selection Criteria 
The next phase of the selection process after selection of articles of 
particular interest has been identified is to refine search by utilising the limit 
strategies within the database and journal articles. This allows more filtering 
which only identifies articles of specific relevance and limits the article to 
review to a more manageable number. PUBMED database may sometimes 
allow free online access to the full text of the articles of interest. Most full text 
of the relevant articles were gained via the electronic resources catalogue of 
the University of Chester (http://libcat.chester.ac.uk). However, if full text of 
the articles could not be retrieved with these options, then interlibrary loan 
service was resorted to provide full text as abstracts are not acceptable for 
review. 
Studies were deemed relevant and included for review if: 
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• Discussed attitudes, views and perceptions about HPV vaccines in      
female, adolescence age group. 
• Sample population comprise of eligible physicians, paediatricians, 
obstetricians     or primary care staff. 
• Methodology is a survey. 
• Articles must be written in English language. 
• Articles must be original studies. 
• Articles published in 2006 to the present, that is, after the approval of 
the vaccine. 
Only articles that conform to all of the mentioned criteria were deemed 
eligible for review. Other articles that did conform to all the mentioned criteria 
were excluded from the review but if found to be relevant, were used to 
support analytic debate. To ensure that articles were not reviewed multiple 
times, duplications were carefully considered. 
Search for this review was not limited to countries as the HPV programme 
has a worldwide implementation. However it was suggested that systematic 
review may sometimes benefit from spatial restrictions because in terms of 
implementation and transferability, country or cultural context may matter 
immensely (Egan, et al., 2009). 
An initial pilot search exercise was carried out for this review. This would be 
beneficial for search strategy to produce an impression of where studies are 
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located, given that it is not necessary or productive for a systematic review to 
search everywhere as suggested by Bambra (2009). 
Harden, et al (2003) states that “methods for systematic reviews are well 
developed for trials but not for non-experimental or qualitative research”. 
Thus, from the context of evidence based medicine, randomized controlled 
trial (RCT) is considered the greatest evidentiary value for assessing efficacy 
of interventions (Jarlais, Lyles, Crepas, 2004) However, Victoria et al., 
(2004) disputed this argument in view of the fact that evidence based public 
health will necessarily involved the use of research designs other than 
randomized controlled trials. They also argued that RCT may not be practical 
and ethical in evaluating many public health interventions. 
People’s perspective and experience, sometime called “view” studies maybe 
difficult to locate as they could not be easily classified as qualitative or 
quantitative and often failed to meet the methodological reporting standards 
use in a newly developed assessment tools (Harden, et al. 2004). 
Bryman (2008), described a survey research as a cross sectional design in 
relation to which data are collected mainly by self completion questionnaire 
or structured interview at a single point in time in order to collect data. It 
could provide a representative and quantitative picture of respondent issues, 
concerns and attitudes (Mills, Montori, Ross, Shea, Wilson & Guyatt, 2005).  
In contrast, qualitative researches   are those that usually emphasizes words 
rather than quantification in the collection and analysis of data (Bryman, 
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2008), therefore, provides insights into emotional and experiential 
phenomena to determine the perspective of those being studied (Giacomini 
& Cook, 2000). 
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4.0. Data Analysis 
4.1 Data collection and Extraction 
Articles selected for systematic review will differ in their aims and objectives, 
outcomes, analysis and overall conclusions, thus, each methodology will 
have different protocol. Therefore, to allow effective comparison between 
studies it is of vital importance that a universal, self explanatory method of 
data extraction and subsequent presentation is used (Black, 2007). The 
following data points were from the research studies included in the review: 
1. Author, with priority on the first author 
2. Date of publication 
3. Date when study was conducted 
4. Place where study was conducted 
5. Type of participants  
6. Number of participants 
7. Method of data collection 
8. Response rate 
9. Outcome 
Data extraction form was developed and pilot tested on two articles.  Once 
remaining modifications were made to the extraction form, one reviewer 
(myself) extracted the data from included studies and records it. If there were 
inadequate data or information for a given outcome, that particular published 
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article was deemed inappropriate for analysis and was therefore excluded 
from the review. 
 
4.2 Quality Criteria and Selection of bias 
As studies included in this review varied in the methods they used, a 
checklist was adapted from Harden et al., 2004. Who authored a study that 
describes the methods developed for reviewing research on people’s 
perspective and experience or “view” studies. 
 Table 2 demonstrates methods of data collection and analysis used as 
adapted from Harden et al (2004). 
Twenty three of twenty nine studies included in the review use fixed 
response self-completion questionnaire, four studies utilised interview and 1 
study each for study that employ fixed and open response self-completion 
questionnaire and another study make use of survey followed by interview.  
Table 3 demonstrate method of analysis used in this review. 
Majority (twenty three of twenty nine) of the studies in this review utilized 
descriptive and/or inferential statistics in the analysis of the data. 
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Table 2 Methods of Data collection and analysis used (n=29) 
 
 
        
Table 3 Methods of Data Analysis (n=29) 
                                                                                             Number             
Descriptive and/or inferential statistics                                23              
Qualitative data analysis                                                     3                 
Combination                                                                        3                 
Total                                                                                    29               
 
 
                                                                                                                                                           Number         
Fixed response self completion questionnaire                            23           
Fixed and open response self completion questionnaire             1            
Open response self completion questionnaire                              0          
 Interviews and/or focus groups                                                    4           
Combination of interview and questionnaire                                 1           
Total                                                                                            29           
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Quality assessment of included studies. 
There are numerous scales available for the assessment of bias and 
control of quality. The introduction of reporting guidelines like Consolidated 
Standards of Reporting Trials (CONSORT), Standards for Reporting Studies 
of Diagnostic Accuracy (STARD) and  Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE), could be employed for 
trials and diagnostic study report presented more likely in a standard way.  
However, because of the limited timeframe to carry out this review and 
assess quality of studies incorporated in this review, a seven quality criteria 
adapted from Harden, et al (2004) were utilized. This quality assessment tool 
may need to be further developed. Nevertheless because it is simple, quick to 
use and could be acceptable to both qualitative and quantitative, it was 
deemed to be most appropriate for this investigation. Table 4 demonstrate the 
checklist and number of studies included in the review meeting each quality 
criterion. 
Table four displays the number of studies meeting the seven criteria as 
reviewed by a single reviewer (myself). Only one study did not met the criteria 
of describing explicitly the aim and objective of the study conducted. Most of 
the studies met the seven criteria for quality assessment, thus, deemed to be 
of good quality.  
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 Table 4. Number of studies included in the review meeting each    quality   
criterion (n=29) 
 
        Criteria                                                                            Number      
1. An explicit theoretical framework and/or                               25 
           literature review 
 
2. Aims and objectives clearly stated                                       28 
 
3. A clear description of context                                               26 
 
4. A clear description of the sample and how it was                24 
            recruited 
 
5. A clear description of methods used to collect                     23 
            analyze data 
 
6. Attempts made to establish the reliability or valid                20 
            of data analysis 
 
7. Inclusion of sufficient original data to mediate between     28 
            evidence and interpretation   
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5.0 Results  
This section of the review will discuss  results from literature search of five 
databases, results of assessment of quality of studies included. Furthermore, 
to present the result clearly, sections will be discussed based on the 
research questions and objectives of this review.   
5.1   Literature search results 
The search from the previously described databases and journal titles yield a 
potential 1,454 articles for review. Upon refinement, and limiting the search 
to incorporate only those applicable to the review, identifying those that met 
the inclusion criteria, as well as disregarding duplication, rejecting editorials, 
commentaries and reviews; excluding those with participants other than 
physicians and done prior to 2007, that before the vaccine approval, a total 
of 29 studies were deemed sufficient enough to be included in the review. 
Other reasons for non-inclusion were: knowledge, attitudes or behaviour of 
physicians are not discussed; sample population is not comprised of 
physicians; articles are not about HPV vaccine, instead about HPV infection 
and screening; about HPV vaccination in males and not in English language. 
The summaries of all 29 studies can be found in appendix 2. 
Figure 1, demonstrate the overall results of the literature search 
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Figure 1.  Flow chart for search and selection of studies for relevant articles 
included in the Systematic Review. 
 
29 studies were included. 
26 studies were further excluded 
  4: commentary, editorial, report,     
     review 
  8: involved nurses, psychologist,      
     midwives, interns as participants    
     aside from physicians 
  5: conducted before 2007 
  5: involved parents as participants              
      aside from physicians 
  3: about male adolescents 
 1: not in English language 
1,454 abstracts were obtained when searching with (HPV OR Human 
papillomavirus vaccine) AND (physician* OR doctor* OR clinician* OR 
practitioner* OR family physician* OR p*diatrician* OR Obstetrics/Gynaecologist* 
OR primary care personnel) AND (views OR behaviour OR attitudes OR 
perceptions)               
1360 abstracts were not relevant 
• knowledge, attitudes or behaviour of 
physicians were not discussed;  
• sample population were not comprised 
of physicians;  
• articles were not about HPV vaccine- 
about HPV screening and HPV infection 
  94 full text papers were reviewed for 
potential inclusion 
39 duplications 
55 studies addressing physicians’ 
knowledge, attitudes and behaviour 
were included for analysis 
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5.2 Characteristics of included articles 
 
As previously stated only papers done after HPV vaccine approval in 2007 
were included in the review. Majority of the studies included were published 
in year 2009 (n=6) and 2010 (n= 9). In accordance with the inclusion criteria 
all studies reviewed were in English language. Likewise, majority of the 
studies were conducted in 2006 (n=8) and 2008 (n=7). From the 29 studies 
included for review, 24 studies used survey method for data collection 
(mailed self- administered questionnaire, n= 15; online self-administered 
questionnaire, n=7; through fax, n=2) while the remaining 4 studies utilized 
in-depth interview method to collect data with 1 study that utilized both 
methods. 
Regarding population characteristics, majority of the study was conducted in 
the USA (n=21) and Australia (n=2) with the remaining studies from each 
countries: Canada, Italy, UK, France, India and Malaysia.  
A greater part of the study was conducted across mixed of populations 
(general/family, obstetrician/gynaecology and paediatricians) with 14 out of 
29 studies followed by studies with paediatricians (n=9) as participants and 
obstetrics/gynaecology with 3 studies. 
Response rate was reported by seven out of 29 studies to be low in their 
limitations of study (Kahn, 2009; Wong, 2009; Tariq, 2009; Askelson, 2010; 
 
45 
 
Brotherton, 2010; Ko, 2010 and Schnatz, 2010).Response rate was 
calculated as the number of surveys returned divided by the number of the 
surveys that were sent and not returned as undeliverable (Roberto, Krieger, 
Katz, Goei & Jain, 2011). This may result to non-response bias. However, 
Grooves (2006) argued that low response rate do not necessarily indicate a 
non-response bias. Compared to the general population, non-response bias 
might not be as critical, which could be accounted to the uniformity of 
knowledge, attitudes and behaviour in particular group of physicians 
(Kellerman & Herold 2001)  
Monetary incentive, imbursement or compensation was identified in eight out 
of 29 studies included in the review (Tissot, 2007; Kahn, 2007; Weiss, 2010; 
Brotherton, 2010; Lutringer-Magnin, 2011; Vadaparampil, 2011; Young, 
2011 and Zimet, 2011).  
On line survey was used in five studies as a method of data collection. 
Kellerman and Herold (2001), found that surveys completed on the web 
among physicians have a tendency to incur a greater non-response bias 
compared to surveys conducted in other modes. This finding was 
contradictory to the result of the study that no response bias exist when web 
and mail was compared. Furthermore, this bias was only present toward 
specialist in the web group (Beebe, Locke, Barnes, Davern & Anderson, 
2007). 
Characteristics of included studies can be referred to in Table 5.  
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Table 5.  Demonstrate the basic characteristics of included studies within systematic review 
 
           (Arranged according to publication year) 
 
First 
author 
Publication    
     Date 
Year 
Survey 
Distributed 
Place Where 
Study 
Completed 
Participants and 
Number 
of Participants 
Response    
    Rate 
Method of 
Data 
Collection 
Tissot 2007 2005 USA Paediatrician 
(n=31) 
Represent 
72% of 
initially 
contacted 
In depth semi-
structured 
interview 
Kahn 2007 2005 USA Paediatrician 
(n=31) 
72% of 
initially 
contacted 
One on one 
interview 
Esposito 2007 2006 Italy Paediatrician 
(n=311) 
77.8% Self-
administered 
questionnaire 
Duval 2007 2006 Canada Paediatrician 
(n=461)  
Obstetrician 
(n=395)    Family 
physician (n=408 
 
51% 
Self-
administered 
questionnaire 
Feemster 2008 2006, 
Decemb
er to 
2007 
Februar
y 
USA Paediatrician 
(n=101) 
59% On line 
questionnaire 
Ishibashi 
 
 
 
2008a 2006   USA Paediatricians 
(n=373) 
50% On line 
survey 
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First 
author 
Publication    
     Date 
Year 
Survey 
Distributed 
Place Where 
Study 
Completed 
Participants and 
Number 
of Participants 
Response 
rate 
Method of 
Data 
Collection 
Ishibashi 2008b 2006   USA Paediatricians 
(n=373) 
50% On line 
survey 
Keating 2008 2007   USA Paediatrician(n=22
) OB/GYN (n=26) 
Family/Gen 
practitioner n=65) 
Internist (n=30) 
74% Interview 
Jaspan 2008 2006 USA Obstetrician 
(n=9) 
Not stated Questionnair
e 
Wong, L 
 
2009 2008 Malaysia General 
physicians 
(n=176)   
29.5% Questionnair
e 
(mailed) 
Hopkins 2009 2007 UK General 
Practice(n=62) 
Paediatrics(n=10
3), Obstetrics 
/Gynaecology 
(n=57) 
23 % On-line 
survey 
Leddy 
 
2009 2007 USA OB/GYN  
(n=3896) 
28.03% Survey 
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First 
author 
Publication    
     Date 
Year 
Survey 
Distributed 
Place Where 
Study 
Completed 
Participants and 
Number 
of Participants 
Response    
    Rate 
Method of 
Data 
Collection 
 
Kahn 
2009b 2008 USA Family Med 
(n=384) 
Paediatrics 
(n=298)  OBGYN 
(n=289) Internal 
med (n=148) 
Other (n=4) 
Not stated On line 
survey 
Tariq 2009 Not 
stated 
USA Family physicians 
(n=821) Internal 
Medicine (n=222) 
Paediatrician 
(n=190) 
 
20.4% 
Questionnair
e 
Huey 2009 2006 USA Primary care 
practitioner(n=55) 
85% Survey 
Askelson 2010 2007 USA General 
physicians 
(n=207) 
 
24.6% Survey 
Weiss 2010 2008 USA Family physicians 
(n=499) 
Paediatrician 
(n=595) 
44.7% Survey 
Tan 2010 2009 Australia Gynaecologist(n=
731) 
49.0% Survey 
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First 
author 
Publication    
     Date 
Year 
Survey 
Distributed 
Place Where 
Study 
Completed 
Participants and 
Number 
of Participants 
Response    
    Rate 
Method of 
Data 
Collection 
Krupp 2010 2008 India OB/GYN (n=6) 
Paediatrics (n=9) 
Family or general 
practice (n=5) 
Not 
recorded 
In depth 
interview 
Brotherton 2010 2008 Australia 
 
General 
practitioner 
(n=298) 
 
32% 
Survey 
Wong 2010 2006-2007 USA General 
practitioner/Family 
practitioner (n= 421), 
OB/GYN (n=333), 
Internal 
Medicine(n=310) 
67.5% Survey 
Ko 2010 2007 USA Internal 
Medicine(n=212), 
Paediatrician 
(n=122), OBGYN 
(n=90) 
28.9% Online survey 
Schnatz 2010 2008 USA Paediatrician 
(n=345) 
32,5% Survey (mail) 
Daley 2010 2008 USA Paediatrician 
(n=429)  Family 
physician (n=419) 
Paediatrici
an (81%)  
Family 
physician  
(79 %) 
Online survey 
and mail 
based on 
participant 
preference 
Lutringer-
Magnin 
2011 2007 to 
2008 
France Paediatrician 
(n=279) 
93% Self-
administered 
questionnaire 
and interview 
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First 
author 
Publication    
     Date 
Year 
Survey 
Distributed 
Place Where 
Study 
Completed 
Participants and 
Number 
of Participants 
Response    
    Rate 
Method of 
Data 
Collection 
Roberto 2011 Not 
recorded 
USA Paediatrician(n=4
06) 
34.7% Survey 
Vadapara
mpil 
2011 2009 USA Family physician 
(n=500), 
Paediatrician 
(n=287), 
Obstetrician & 
Gynaecology 
(n=226) 
Not recorded Survey 
Young 2011 2007 USA Family 
practitioners 
(n=169); 
Obstetrician  & 
Gynaecologist 
(n=216) 
 
48.7% 
Survey 
Zimet 2011 2008 USA Family/General 
physician 
(n=113); OB/GYN 
(n=158) 
 
34.0% 
Survey 
through fax 
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Studies included in the review posed a variety of objective, design and 
method of data collection and analysis. In order to simplify analysis, 
outcomes were classify whether focus was given or attitudes, described in 
this review as physicians’ intention or recommendation to provide the HPV 
vaccine. Studies that identified and listed barrier were group as to what 
barrier and factor to provide framework for analysis. 
Table 6 demonstrate the included studies for the review with its objective, 
focus and identification of the barriers for vaccination. 
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Table 6.Included studies in the review by its objective, focus and barrier of vaccination discussed 
 
 
 
First 
author 
Publication 
Date 
Year 
survey 
distributed 
Place 
where 
study 
completed 
Participant
s and 
number of 
participants
Method 
of data 
collection 
Objective of the study Knowl
edge 
focus
Attitude
focus 
Barriers 
Tissot 2007 2005 USA Paediatrician 
(n=31) 
In depth 
semi-
structured 
interview 
Examine paediatricians views about key 
issues related to HPV vaccine delivery 
and identify their strategy for effective 
vaccine delivery 
No Yes  Yes 
Kahn 2007a 2005 USA Paediatrician 
(n=31) 
One on one 
interview 
Describe the range of paediatricians’ 
attitudes about HPV and explore factors 
influencing their  intention to recommend 
HPV 
No  No  Yes 
Esposito 2007 2006 Italy Paediatrician 
(n=311) 
Self-
administere
d, 
anonymous 
questionnai
re 
Evaluate knowledge and attitudes 
regarding HPV and its prevention 
Yes Yes Yes 
Duval 2007 2006 Canada Paediatrician 
(n=461)  
Obstetrician 
(N=395)    
Family 
physician 
(n=408) 
Self-
administere
d 
questionnai
re 
Assess knowledge, attitudes and beliefs 
about HPV infection and prevention as 
well as factors associated with 
willingness to prescribe HPV vaccine 
No Yes Yes 
Ishibashi 2008a 2006 USA Paediatricians 
(n=373) 
On line 
survey 
Examine whether paediatrician would 
recommend the vaccine, obstacles they 
encountered and characteristic with not 
recommending to eligible patients 
No Yes Yes 
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First 
author 
Publication 
Date 
Year 
survey 
distributed 
Place 
where 
study 
completed 
Participant
s and 
number of 
participants
Method 
of data 
collection 
Objective of the study Knowl
edge 
focus
Attitude
focus 
Barriers 
Ishibashi 2008b 2006 USA Paediatrician 
(n=373) 
On line 
survey 
Determine paediatricians attitudes about 
HPV and to compare their attitudes with 
those expressed by the general public 
No Yes No 
Keating 2008 2007 USA Paediatrician(
n=22) 
Obstetrician/g
ynaecologist(
n=26)        
Family/ Gen 
practitioner 
(n=65)        
Internist 
(n=30) 
Interview Provide an overview of potential barriers 
to provision of HPV vaccine and 
empirical data on the concerns of 
medical practices that may inhibit 
vaccine provision 
No Yes Yes 
Jaspan 2008 2006 USA Obstetrician 
(n=9) 
Questionna
ire 
Determine the percentage of patients 
vaccinated per individual provider and to 
document attitudes  and reasons for the 
acceptance of the vaccine 
No Yes  Yes 
Wong 
 
2009 2008 Malaysia General 
physicians 
Questionna
ire(mailed) 
Determine physicians’ experiences in 
providing HPV vaccination 
No Yes Yes 
Hopkins 
 
2009 2007 UK General 
practice 
(n=62)  
Paediatrician 
(n=103)Obste
trics and 
gynaecology 
(n=57) 
On line 
survey 
Investigate the willingness of clinicians to 
recommend HPV vaccine and to 
determine factors affects their willingness 
No Yes Yes 
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First 
author 
Publication 
Date 
Year 
survey 
distributed 
Place 
where 
study 
completed 
Participant
s and 
number of 
participants
Method 
of data 
collection 
Objective of the study Knowl
edge 
focus
Attitude
focus 
Barriers 
Leddy 
 
2009 2007 USA Obstetrician 
and 
gynaecology 
(n=3896) 
Survey Examine obstetricians and 
gynaecologists’ practices, opinions and 
knowledge regarding HPV vaccine 
Yes Yes Yes 
Kahn 2009b 2008 USA Family 
medicine 
(n=384) 
Paediatrics 
(n=298) 
Obstetrics 
and 
gynaecology 
(n=289) 
Internal 
Medicine 
(n=147) Other 
(N=4) 
 
On line 
survey 
Examine physicians’ recommendations 
for the quadrivalent HPV in 11-12 year 
old girls, intention to recommend HPV 
vaccines to 11-12 year old boys and 
attitudes about mandated HPV 
vaccination for 11-12 year old girls 
No  Yes Yes 
Tariq 2009 Not stated USA Family 
physicians 
(n=821) 
Internal 
Medicine 
(n=222) 
Paediatrician 
(n=190)  
Questionna
ire 
Assess attitudes about the HPV vaccine; 
to expose barriers that physician 
encounter when prescribing or 
administering the HPV vaccine  
No Yes Yes 
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First 
author 
Publication 
Date 
Year 
survey 
distributed 
Place 
where 
study 
completed 
Participant
s and 
number of 
participants
Method 
of data 
collection 
Objective of the study Knowl
edge 
focus
Attitude
focus 
Barriers 
Huey 2009 2006 to 
2007 
USA Family 
Medicine/ 
Paediatrician/
Obstetrician 
and 
Gynaecology 
(n=55) 
Survey 
through fax 
Assessed attitudes and practices related 
to HPV vaccination 
No Yes Yes 
Askelson 2010 2007 USA General 
physicians 
(n=207) 
Survey Assess factors related to physicians’ 
intention to  vaccinate patients against 
HPV 
No Yes Yes 
Weiss 2010 2008 USA Family 
physicians 
(n=499) 
Paediatrician 
(n=595) 
Survey Assess physicians’ attitudes and 
perceptions regarding potential HPV 
vaccination of males 
Yes 
 
 
Yes
No 
Tan 2010 2009 Australia Gynaecologis
t 
Survey Established the attitudes of 
gynaecologist to HPV vaccination when 
advising women in various age groups 
No  Yes No 
Krupp 2010 2008 India Obstetrics & 
gynaecology 
(n=6) 
Paediatrics 
(n=9) Family 
or general 
practice (n=5) 
 
In depth 
interview 
Investigate  physician intention-to-
recommend the HPV vaccine to parents 
of adolescent girls 
No Yes Yes 
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First 
author 
Publication 
Date 
Year 
survey 
distributed 
Place 
where 
study 
completed 
Participant
s and 
number of 
participants
Method 
of data 
collection 
Objective of the study Knowl
edge 
focus
Attitude
focus 
Barriers 
Brotherton 2010 2008 Australia General 
practitioner 
(n=298) 
Survey Investigate general practitioners’ 
experiences of delivering the HPV 
vaccine to women aged 18 to 26 
No No Yes 
Wong 2010 2006-2007 USA General 
practitioner/F
amily 
practitioner 
(n= 421), 
Obstetrics 
and 
gynaecology(
n=333), 
Internal 
Medicine(n=3
10) 
Survey Evaluate physician intentions regarding 
HPV vaccine’s impact on future 
screening. 
No No No 
Ko 2010 2007 USA Internal 
Medicine(n=2
12), 
Paediatrician 
(n=122), 
Obstetrics & 
gynaecology(
n=90) 
On line 
survey 
Compare physician practices, attitudes 
and barriers toward human 
papillomavirus (HPV) vaccination 
Yes Yes Yes 
Schnatz 2010 2008 USA Paediatrician 
(n=345) 
Survey 
(mail) 
Investigate practitioner acceptability of 
the recommendation to offer the human 
papillomavirus (HPV) vaccine to 
adolescent women 
Yes Yes Yes 
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First 
author 
Publication 
Date 
Year 
survey 
distributed 
Place 
where 
study 
completed 
Participant
s and 
number of 
participants
Method 
of data 
collection 
Objective of the study Knowl
edge 
focus
Attitude
focus 
Barriers 
Daley 2010 2008 USA Paediatrician 
(n=429), 
Family 
physicians 
(N=419) 
Survey 
(online and 
through 
mail based 
on 
participants 
preference) 
Assess HPV vaccination practices, 
perceived barriers to vaccination and 
factors associated with whether 
physicians strongly recommend HPV 
vaccine to 11 to 12 year old 
No Yes Yes 
Lutringer- 
Magnin 
2011 2007 to 
2008 
France Paediatrician 
(n=279) 
Self-
administere
d 
questionnai
re and 
interview 
Examine the perception, attitudes and 
practices of GPs in relation to HPV  
No Yes Yes 
Roberto 2011  USA Paediatrician Survey Examines the ability of theory of 
reasoned action and theory of planned 
behaviour to predict whether or not  
paediatricians encourage parents to get 
their adolescent daughters vaccinated 
against HPV 
No Yes No 
Vadaparam
pil 
2011 2009 USA Family 
physician 
(n=500), 
Paediatrician 
(n=287), 
Obstetrician & 
Gynaecology 
(n=226) 
Survey Determine the prevalence of physician 
recommendation of HPV vaccination in 
early ages (11-12), middle (13-17) and 
late adolescent (18-26); identify factors 
associated with recommendation in early 
adolescents 
No Yes Yes 
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First 
author 
Publication 
Date 
Year 
survey 
distributed 
Place 
where 
study 
completed 
Participant
s and 
number of 
participants
Method 
of data 
collection 
Objective of the study Knowl
edge 
focus
Attitude
focus 
Barriers 
Young 2011 2007 USA Family 
practitioners 
(n=169); 
Obstetrician  
& 
Gynaecologis
t (n=216) 
Survey Evaluate use of the HPV vaccine, 
attitudes and  barriers among 
gynaecologist and family practitioners 
between the 2 specialties 
No Yes Yes 
Zimet 2011 2008 USA Family/Gener
al physician 
(n=113); 
Obstetrics/gy
naecology(n=
158) 
Survey 
through fax 
To determine whether physicians 
consider the patient’s relationship status 
or HPV/Pap testing history when 
deciding whether to recommend the HPV 
vaccine to women ages 19-26.   
No Yes No 
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.3. Question one. “What are the physicians’ attitudes towards HPV vaccination? 
Twenty five studies were found to have reported physicians’ attitudes in their 
findings. Attitudes by physician were linked on their intent to vaccinate their 
patients against HPV vaccine and their recommendation for their patients to 
vaccinate against HPV. Kahn (2007) and Askelson (2010) described physicians’ 
attitude as positive.  Esposito (2007) illustrate in his study of Italian physicians 
that majority intent to recommend the vaccine to female adolescent and more 
likely to males. This finding was also reported by Kahn (2009), Roberto (2011), 
Lutringer-Magnin (2011), Tariq (2009) as well as Weiss (2010). Kahn(2009) 
rationalized that physicians may be more willing to recommend  the HPV vaccine  
to boys now than in the past because more data are available about the efficacy 
and safety of HPV vaccine in girls  and clinicians maybe more aware of HPV 
related disease in men. Physicians from Canada professed higher intent to 
recommend the HPV vaccine if it publicly funded (88 percent) and only would not 
likely (84 percent) if patients have to pay for the vaccine. 
Studies involving  obstetrics and gynaecology as participants (Tan, 2010 & 
Jaspan 2008) also show strong  support for HPV vaccine although gynaecologist 
from the latter mentioned study do not see themselves in the traditional role as 
vaccinators.. 
Physicians from less developed countries like India (Krupp, 2010), expressed 
positive attitude toward HPV vaccination in general, although majority believed 
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that few of their patients would react positively to a vaccine recommendation. 
Practicing OB/GYN suggested that recommending immunization was not 
appropriate in their work setting, which could likely be a factor of constrain in the 
promotion of HPV vaccination. In addition, a physician pointed out patient load 
was perceived as an obstacle in promoting the vaccine. 
Another study from less developed multi ethnic country, Malaysia,  Wong (2009), 
view HPV vaccine as great promise in cervical cancer prevention. However, 
cultural sensitivity is an issue of consideration by Malay Muslim physicians when 
recommending HPV vaccine. Physicians agreed that better acceptance would 
benefit the target population if HPV vaccine is recommended for cervical cancer 
than sexually transmitted disease. 
Six authors described knowledge of physician regarding HPV in their studies 
(Esposito, 2007; Feemster, 2008; Hopkins, 2009; Leddy, 2009; Brotherton, 2010 
and Schnatz, 2010). Majority of these studies exemplify physicians’ knowledge 
about HPV vaccine. However, Esposito (2007), demonstrate  in his study about 
Italian physicians’ knowledge to be poor concerning HPV disease, and its 
prevention. Although, majority would still recommend HPV vaccination. 
Hopkins (2009), pointed out findings in his study of UK physicians’ that self-rated 
knowledge of the HPV vaccine was an important determinant of willingness to 
recommend vaccination. 
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Question 2. What are the factors that influence physicians’ decision in 
administering     HPV vaccine? 
This section of the review will focus on the factors identified from the studies 
considered as barriers to their intent to vaccinate their patients against HPV 
infection. 
Of the 29 studies included in the review, 23 made some mentioning of barriers in 
physicians’ intent to vaccinate their patients for HPV vaccine. The following 
patterns regarding barriers for intention to provide vaccine will be discussed. 
1. Cost of the vaccine and/or  problem with reimbursement  
Cost of the vaccine or problem with reimbursement was identified in 13 of 29 
studies (Kahn,2007; Ishibashi, 2008a; Keating, 2008; Jaspan, 2008; Wong, 
2009; Leddy, 2009; Kahn, 2009; Tariq, 2009; Huey, 2009; Krupp, 2010; Ko, 
2010; Daley, 2010 and Young, 2011). 
Physicians delivering HPV vaccine through clinic based considered cost of 
the vaccine as the most important factor preventing them from providing 
vaccine to their patients. High cost of the vaccine and inadequate 
reimbursement were consistent concern of most physicians. 
Wong (2009), in her study in a developing country like Malaysia, found out 
that physician viewed high cost of the vaccine as a great challenge. With no 
public source of funding for HPV vaccine and the burden cause by the three 
doses vaccine to an average Malaysian household income, cost of the 
vaccine would remain to be an important contributing factor that limits its use. 
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This same finding was also identified by Krupp (2010) as a perceived barrier 
in his study conducted in India. 
Leddy (2009), described results from her study, that many physicians agreed, 
cost is a reason for patient refusal and a deterrent from mandating the 
vaccine. 
Tariq (2009) pointed out affordability of vaccine to a significant barrier in his 
studies, identifying the cost of the vaccine as more expensive than most 
vaccine. 
 
2. Providers concern about vaccine’s safety and efficacy. 
Three of the twenty nine studies discussed about provider’s issues of concern 
regarding safety and efficacy of the vaccine, which may result to be   a barrier 
in vaccine promotion. These studies were authored by the following: Kahn 
(2007), Ishibashi (2008a), and Jaspan (2008). 
Kahn (2007) found out in his study that physicians were concerned that HPV 
immunization could have an adverse effect. Beliefs about efficacy by the 
physicians is related to immunogenicity, primarily about the decline of 
protection by the time adolescents become sexually active and non-
compliance with three doses could lead to suboptimal immune response. 
Concerns towards safety by patients were considered as a provider’s barrier to 
the acceptance of the vaccine (Jaspan, 2008). 
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3. Parental concern over vaccine’s safety and efficacy.  
Parental barrier over vaccine’s safety and efficacy was reported in their 
studies by Kahn (2009), Feemster (2008), Wong (2009), Ko (2010), Lutringer-
Magnin (2011) and Schnatz (2010).  
Schnatz (2010), discussed findings about unknown long term effect of the 
vaccine and the belief that their child is not yet sexually active were the 
reasons provided to their physicians by parents of adolescent girls who chose 
not to have their children vaccinated with HPV. 
Ko (2010) reported that the most frequently encountered barrier for 
vaccination by the paediatricians are parental fear for the vaccine’s adverse 
effects. 
4. The age of the adolescent is considered too young for vaccination. 
 Wong (2010), Huey (2009), Vadaparampil (2011) and Kahn (2009), 
particularly mentioned age of the target populations to    be too young for 
vaccination.  
Vadaparampil found out that most physicians would not recommend HPV 
vaccine to the younger age group of 11 to 12 years old. 
5. The issue that HPV vaccine could promote sexual activity. 
Huey (2009) and Krupp (2010) reported from the result of their studies that 
issues about HPV vaccination could promote risky sexual behaviour was 
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considered as a barrier for providing the vaccine particularly on the parental 
perspective. 
 Ishibashi (2008a) described providers’ concern about vaccines’ impact on 
adolescents’ sexual activity. 
HPV vaccine may encourage sexual activity was recorded by  Ko (2010) and 
Wong (2009) on their studies.  
However, Tariq (2009) discussed in his study that physicians did not believe 
HPV vaccine increased patients’ sexual activity. 
6. Recommendation of HPV vaccine from organization. 
Two studies showed findings that providers are more inclined to provide 
vaccination if it is recommended by influential organisation Tissot (2007) and 
Askelson (2010). The latter discussed that intent for vaccination usually follows 
organisation recommendation and its importance of recommendation is highly 
considered by the providers. 
7. Communication related to sexuality. 
Esposito (2007) reported that paediatricians’ propensity not to talk about 
question related to sexuality with their patient’s parents could represent a 
barrier for vaccination. Likewise, Daley (2010) emphasized the necessity of 
discussing sexuality before recommending the HPV vaccine. 
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8. Need for education.  
Esposito (2007), Krupp (2010), Brotherton (2010) and Wong (2010) discussed 
in their studies that education about HPV vaccine should be highlighted to the 
providers in order to promote vaccination. 
 
9. Other factors 
Other factors considered in the review were: sex, that men should also be 
vaccinated for HPV by Tariq et al., (2009); the latter likewise discussed dosing 
of the HPV vaccine could posed a barrier for vaccination; another factor 
considered by Krupp et al., (2010) to be a barrier in HPV vaccination is 
workplace constraints and load of patients in their clinic and Tissot et al., 
(2007) discussed parental religious beliefs could affect vaccine acceptability. 
 
Question no. 3. Is there difference in the views of different medical 
specialties with regards to HPV vaccination? 
This section of the review focus on the different views and attitudes of three 
medical specialties involved in the included studies.  
As the participants of the studies in the review are influence by their 
demographic and practice patterns between specialties it is deemed 
inappropriate to compare individual views of each specialty. However, for the 
purpose of this review, those studies with comparison between specialties and 
maybe relevant to the review will be discussed.  
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Although, 14 studies of 29 included in this review covered mixed participants 
across specialties, comparison will be incongruous as often result and 
conclusion derived from the study are frequently generalized or conclusion 
cannot be drawn. Participants are described at the methodology but in the 
result it is always collectively presented. 
Four studies that discussed comparison of medical specialty views regarding 
HPV vaccine were: 
• Young (2011), compared gynaecologist and family physician in the 
rates of providing HPV vaccine in their clinics in  which  found he found    
no significant deference between the two specialties. 
• Daley (2010), who reported that vast majority of paediatricians and 
family physicians are offering the vaccine to their patients although 
fewer physicians for both specialties, strongly recommended the 
vaccine for 11 to 12 year old patients than for older. 
• Vadaparampil (2011), who surveyed  family physicians, paediatricians 
and Obstetrics & Gynaecology and found that paediatricians are more 
likely to recommend the HPV vaccine 
• Ko (2010), identified different barriers between specialties. For internist 
and obstetrician and gynaecology, the greatest barrier is reimbursement 
concern while paediatricians reported adverse effects of the vaccine.   
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6.0   DISCUSSION 
This section of the review summarises the major findings from the papers 
included in the review, describes the  limitations of the included studies  details, the 
strengthes and weaknesses of  review methods, discusses the results in the context of 
other knowledge, implications for current practice and suggestions for future work. 
The systematic review was carried out to assess physicians’ attitudes towards HPV 
vaccine and to identify factors that influence their intent in providing HPV vaccine to the 
target group, the adolescent girls. Another objective of this review is to understand 
differences in views about HPV vaccine by the different medical specialties involved in 
delivering the HPV vaccine. The searches revealed that the majority of the studies 
demonstrate physicians’ positive attitudes towards HPV vaccine. Most physicians 
showed support and intent to provide the vaccine to the adolescent girls. This strong 
support and recommendation was based on perceived susceptibility of the target 
population and likelihood of benefit. However, as this review explored more of the 
factors that  inhibit them to provide the HPV vaccine and identified in this review as 
‘barriers’ for intention, the  focus of the discussion will be on these factors. The cost of 
the vaccine and problems with reimbursement is the most important factor identified in 
majority of the studies. Other factors were: providers concern about vaccine safety and 
efficacy; parental concern over vaccine safety and efficacy; age of adolescents is 
considered too young for this particular vaccination; the issue that HPV vaccine could 
promote sexual activity; recommendation of HPV vaccine from organisations; 
communication related to sexuality; the need for education regarding HPV vaccine and 
other factors such as sex, a recommendation that boys should also be given the HPV 
vaccine, a three series vaccine could pose a problem with compliance, workplace and 
patients load in the clinic as well as cultural and religious beliefs were listed.  
In terms of the difference in the views of different medical specialties particularly 
general/family physician, paediatrician and obstetrics/gynaecology with regards to HPV 
vaccination, formulating comparison can be ambiguous as these specialties are 
influence by their demographic or practice patterns. However, four studies that 
described comparison between specialties revealed no significant difference between 
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gynaecologist and family physician with regards to the rates of providing the vaccine 
during clinic visits (Young, et al., 2011); fewer paediatricians and family physicians 
recommend the vaccine to 11 to 12 year old  than to older girls (Daley, et al. 2010); a  
survey among family physicians, obstetrics/gynaecology and paediatricians revealed 
that the latter would more likely recommend the HPV vaccine (Vadaparampil et al., 
2011) and Ko et al.(2010) discussed different barrier for each specialty. 
The review is limited by demographic background. Majority of the studies, 21 of 29 
studies included   were conducted in the USA thus, results cannot always be 
generalised. With its characteristic health system and clinic based delivery of the 
vaccine, it will be apparent that cost of the vaccine and reimbursement will be the key 
barrier in vaccination. Thus, raising doubts whether this factor will also come out as a 
primary factor in other countries with different health system and vaccine delivery. 
Interestingly, cost is not only identified in developed countries as developing country like 
Malaysia also reported cost as the primary barrier for vaccination. 
The strength of this review is that it includes studies conducted recently; nine studies in 
2010 and five studies in 2011 were published respectively. Thus, reflecting, attitudes of 
physicians after approval and implementation of the vaccine. Furthermore, adherence to 
guidelines  was also recognized. For example, review of studies showed that most 
physicians are not recommending the vaccine to younger age group of adolescents, 
with the perception that the recommended age which is 11 to 12 year old is too young 
or too low for vaccination. 
The weakness of the systematic review is not utilising a standard tool to reduce bias. 
The studies included in this review are a mix of qualitative and quantitative study, hence 
to limit and assessed quality of the studies, a checklist was developed and adapted 
from a study that also aimed to review people’s perspective and experiences or called 
the “view” studies (Harden, et al., 2003). This checklist was deemed appropriate to use 
as it is extensive but simplified and time saving to a review with a limited timeframe. 
Another weakness of the review is the use of sole researcher. Higgins (2008) and 
Petticrew (2001), emphasized the importance of two reviewers in systematic review to 
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select and critically appraise studies independently   as well as to check data extraction. 
This is important in terms of methodological rigour and prevention of bias but also 
beneficial in terms of sharing the workload and ensuring that there is a support 
throughout the review process (Bambra, 2009).  
Attitudes of physicians before the approval of the HPV vaccine in 2006 (Riedesel, 
Rosenthal, Zimet, Bernstein, Huang & Lan, 2005; Kahn, Zimet, Bernstein, Riedesel, Lan 
& Huang, 2005 and Raley, Fellowwill, Zimet & Ault, 2004) revealed willingness to 
recommend the vaccine and the attitudes of physicians from this review revealed similar 
findings. Survey question during pre-licensure time were still hypothetical as vaccines 
are not yet available, however, it is interesting to know that providers intention did not 
vary in time and with the availability of the vaccine.  
A recent review done with parents to assess their knowledge, attitudes and behaviours 
towards HPV vaccination for their children from 2001 to 2011, revealed that the key 
barrier for HPV vaccination among parents is the safety concern of the newly approved 
vaccine. In contrast, in this review, it was found out that the cost of the vaccine and 
issue of reimbursement was considered the primary barrier for vaccination among 
parents. 
Likewise, age as barrier for acceptability of HPV vaccine (Dempsey, Abraham, Dalton, 
Ruffin, 2009) as previously mentioned is consistent with the current finding in this review 
that most physician would not recommend the vaccine to younger age group (Wong, 
2009; Huey et al., 2009; Vadaparampil, et al., 2011& Kahn et al., 2009). 
Furthermore, as the physician’s role is highly acknowledged in the recommendation and 
delivery of the vaccine, particularly the paediatrician (Ziv, Boulet & Slap, 1999 & Rand, 
Shone, Albertin, 2007) that play a particularly important role in HPV vaccine delivery to 
11 to 12 year old adolescent girls, more effort should be exerted to reached out this age 
group and diminished missed opportunities of immunisation. 
In terms of future implications of policy, in order to promote and preserve the health of 
the population, with the only vaccine available to prevent cervical cancer in the future, 
availability of the vaccine at lower cost should be supported as well as providing HPV 
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vaccine through a school-based approach. If it should be a national program, then it 
should be accessible to most people. Education would be beneficial to a new vaccine 
for its promotion not only to the physicians but to the public as well. In addition, 
campaign against belief that the vaccine would promote high risk sexual activity should 
be encouraged.  
As compliance is another drawback for a three dose vaccine, future studies should 
focus on the efficacy of limited number of doses which could offer adequate protection.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
71 
 
7.0 CONCLUSION  
Physicians’ attitude towards HPV vaccine is consistently positive before licensure 
and post licensure of the vaccine. Hence, their role is still important in the 
implementation and improving uptake of HPV vaccine. Barriers should be overcome to 
increase vaccine acceptability. 
Numerous studies had been done regarding HPV vaccine, however to my 
knowledge and upon extensive data base search, no systematic review exploring 
physicians’ attitudes toward HPV vaccine had been done to date. Researcher in the 
future could make a comprehensive research on the acceptability of HPV on each 
country, to compare, contrast and evaluate its success or failure, considering that the 
vaccine has been instigated for five years.   Hence, policy and guidelines could be 
further improved, implementation could be enhanced, and uptake will be maximized. 
It is with optimism that by recognizing barriers to HPV vaccination, public health 
impact could be created; therefore, appropriate action could be developed and 
accomplished. 
For a public health programme to succeed, it should meet the needs of its target 
beneficiaries.  
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